MedStar Georgetown University Hospital has highlighted a single-port robotic breast cancer operation in which surgeons combined bilateral nipple-sparing mastectomy, sentinel lymph node biopsy, immediate implant reconstruction and nerve-sparing techniques through a concealed 4-centimeter incision. The procedure, performed on June 25, 2026, and highlighted again by MedStar Health on October 12, involved a 50-year-old woman with early-stage breast cancer and used Intuitive Surgical’s da Vinci SP robotic surgical system.
The operation was performed by Lucy De La Cruz, chief of the Breast Surgery program at MedStar Georgetown University Hospital and system chief of Breast Surgery at MedStar Health, in collaboration with plastic surgeon Kenneth Fan. According to the hospital, the surgical team removed breast tissue while preserving the nipples, assessed the sentinel lymph nodes, inserted permanent breast implants and used a nerve-sparing approach intended to protect breast sensation. The patient returned home within hours of the procedure, although the institution did not disclose operative duration, surgical pathology, quantified pain scores or postoperative sensory measurements.
The case illustrates how robotic technology is being incorporated into increasingly complex breast surgery workflows, particularly when cancer treatment and immediate reconstruction are performed together. However, it is an account of a surgical procedure rather than a controlled clinical study demonstrating that robotic mastectomy improves survival, reduces recurrence or preserves sensation more effectively than conventional surgery. The United States Food and Drug Administration has also stated that no robotically assisted surgical device has received marketing authorisation specifically for mastectomy or cancer treatment, making careful assessment of oncological outcomes and patient selection essential.
How did surgeons combine mastectomy, reconstruction, lymph node biopsy and nerve preservation in one operation?
The surgical approach brought together four distinct components of breast cancer care within a single operative session. The bilateral nipple-sparing mastectomy involved removing breast glandular tissue while retaining the overlying skin and nipple-areolar complexes. A sentinel lymph node biopsy was also performed to assess lymph nodes that could provide information about whether the cancer had spread beyond the breast.
Following removal of the breast tissue, the surgical team placed permanent breast implants during the same operation. The reconstruction was performed without supporting mesh, according to an earlier MedStar Health disclosure in August. This approach avoided a separate staged implant-exchange procedure, although whether immediate permanent implantation is appropriate depends on tissue viability, cancer treatment requirements and individual reconstructive considerations.
The fourth component involved a nerve-sparing approach intended to reduce the loss of breast sensation associated with mastectomy. Preserving the nipple and surrounding skin does not necessarily preserve the nerves responsible for sensation, making this an important functional consideration beyond cosmetic appearance. However, the institution has not released objective postoperative sensory testing demonstrating how much sensation was retained or recovered in this patient.
The case is distinctive because these elements were integrated through an incision hidden beneath the breast. In many robotic nipple-sparing procedures, surgical access is created near the armpit or lateral chest wall. The MedStar Georgetown team instead used the natural inframammary fold to conceal the surgical opening while completing the combined treatment and reconstruction.
Why could the da Vinci SP system offer advantages during nipple-sparing mastectomy?
The da Vinci SP system is designed to support minimally invasive surgical procedures through a single access site. Its camera and articulating instruments allow surgeons to operate within confined anatomical spaces while controlling instrument movements from a surgical console. The system does not independently perform the operation, and its effectiveness depends on the surgeon’s experience, procedural planning and appropriate patient selection.
In breast surgery, the potential technical advantage involves accessing tissue through a small incision while maintaining visualisation of structures that need to be dissected or preserved. Robotic instruments may facilitate controlled dissection around the skin envelope and nipple-areolar complex, where maintaining adequate tissue integrity is important. These characteristics could be useful when the surgical objective includes both cancer removal and immediate reconstruction.
The concealed incision also changes the cosmetic profile of surgery. Conventional nipple-sparing mastectomy can preserve much of the breast’s external appearance, but scars may remain visible depending on incision placement. Positioning a smaller incision beneath the breast could reduce its visibility, although cosmetic outcomes depend on healing, breast anatomy and the reconstructive result.
MedStar Georgetown stated that the procedure may reduce postoperative pain, accelerate recovery and leave less noticeable scarring. Those are potential advantages rather than comparative outcomes established by this case. The institution did not report a control group, standardized pain assessments or recovery measurements sufficient to demonstrate that the robotic operation was superior to conventional nipple-sparing surgery.
Can robotic nerve-sparing surgery preserve breast and nipple sensation after mastectomy?
Loss of breast sensation remains an important concern following mastectomy, even when the nipples and skin envelope are preserved. Sensory nerves can be divided during removal of breast tissue, affecting touch, pressure, temperature perception and other forms of sensation. Reconstruction can restore breast contour without necessarily restoring the original sensory function.
Several surgical approaches are being investigated to address this limitation. Nerve preservation seeks to retain suitable existing nerve pathways where oncologically appropriate, while neurotization involves connecting nerves or using grafts to support sensory recovery. These techniques have different anatomical requirements and should not be considered interchangeable merely because both aim to improve sensation.
Published research provides encouraging evidence for sensory-preserving reconstruction. A prospective study involving 47 women and 79 reconstructed breasts reported that more than 80% of patients achieved good-to-excellent results on specified sensory assessments six months after nipple-sparing mastectomy with neurotization. However, the findings involved a particular reconstructive approach and cannot establish the sensory outcome of MedStar Georgetown’s single-port procedure.
A separate prospective cohort study involving 132 patients found improvements in several patient-reported outcomes among women undergoing breast neurotization compared with reconstruction without neurotization. These included measures of nipple sensation, psychosocial well-being and sexual well-being. The findings support the clinical relevance of sensory recovery, although observational comparisons may be influenced by patient selection, surgical technique and other differences between treatment groups.
For the MedStar Georgetown case, the essential unanswered question is whether the nerve-sparing approach produced sustained functional benefit. Objective sensory testing at defined postoperative intervals, together with patient-reported outcomes, would provide stronger evidence than confirmation that a nerve-preserving technique was attempted. Longer follow-up would also help determine whether sensation remains stable or changes as healing progresses.
What does existing research reveal about robotic versus conventional nipple-sparing mastectomy?
The published evidence surrounding robotic nipple-sparing mastectomy has expanded, but it remains less mature than the evidence supporting conventional breast surgery. Comparative research has examined operative time, complications, tissue viability, cosmetic outcomes and cancer-related endpoints. Results have generally supported technical feasibility in selected patients, although differences in study design and follow-up limit definitive conclusions.
A June 2026 systematic review published in the World Journal of Surgical Oncology assessed three prospective comparative studies involving robotic and conventional nipple-sparing mastectomy with immediate implant reconstruction. The analysis found that robotic surgery was associated with an average operative time approximately 64 minutes longer than conventional surgery. It did not identify statistically significant differences in major complications, nipple-areolar complex viability or hospital length of stay.
The review also rated the overall certainty of the evidence as low because of limitations involving study design, sample size and differences between patient populations. Consequently, the absence of a statistically significant difference in complications should not be interpreted as proof that the procedures carry identical risks. The findings suggest that robotic approaches can be feasible in experienced centres, while their comparative advantages remain incompletely established.
A broader 2026 meta-analysis involving 12 studies and 2,312 patients reported lower rates of some postoperative complications with robotic nipple-sparing mastectomy. However, most included studies were non-randomized, and follow-up was relatively limited for evaluating long-term cancer outcomes. Differences in patient selection, surgeon experience and reconstructive techniques remain relevant when interpreting these findings.
The MedStar Georgetown operation adds an example of procedural integration rather than comparative evidence. Its combination of bilateral mastectomy, immediate implants, nodal assessment and nerve preservation demonstrates what a specialised surgical team can accomplish technically. Whether this model produces better outcomes requires systematic follow-up and comparison with established approaches.
What FDA regulatory considerations apply to robotic breast cancer surgery?
An important distinction concerns the regulatory status of the da Vinci SP platform and its use for mastectomy. The United States Food and Drug Administration has cleared robotically assisted surgical devices for various specified procedures, but it has not granted marketing authorisation to any robotic surgical system specifically for mastectomy or for preventing or treating cancer. The availability of the technology for other surgical applications does not establish FDA clearance for this particular cancer operation.
The agency has previously cautioned that the oncological safety and effectiveness of robotically assisted mastectomy have not been established through sufficient evidence. Specifically, questions remain about cancer recurrence, disease-free survival and overall survival compared with conventional treatment. These outcomes require longer observation than the immediate surgical recovery period.
That regulatory distinction does not mean the FDA has determined that robotic mastectomy is ineffective or that physicians are categorically prohibited from using legally marketed devices within medical practice. Rather, the agency distinguishes between authorised device indications and clinical uses for which cancer-specific safety and effectiveness have not been established. Hospitals adopting these techniques must therefore assess the available evidence, ensure appropriate professional oversight and communicate the relevant uncertainty.
For cancer surgery, the central objective remains adequate removal of malignant tissue while protecting patient safety. Smaller incisions and immediate reconstruction are valuable considerations, but they cannot substitute for appropriate surgical margins, nodal assessment and subsequent cancer management. The MedStar Georgetown announcement did not disclose pathology results or long-term oncological follow-up, so conclusions about the patient’s ultimate cancer outcome cannot be drawn from the reported procedure.
Which breast cancer patients may be suitable for single-port robotic nipple-sparing surgery?
MedStar Georgetown identifies selected patients with small to moderate-sized breasts, appropriate nipple positioning and a healthy body weight as potentially suitable candidates for the procedure. These anatomical characteristics can influence the ability to access breast tissue safely through a concealed incision while maintaining adequate visibility and instrument movement. Patient suitability also depends on cancer-related factors that must be evaluated independently of the reconstructive objective.
The hospital states that the technique is not recommended for patients with larger or significantly sagging breasts or those with inflammatory breast cancer. Larger breast volume and certain breast shapes may complicate dissection and reconstruction through a restricted access site. Inflammatory breast cancer presents different oncological requirements, making the nipple-sparing approach unsuitable in that setting.
Other considerations may include tumor location, involvement of the skin or nipple-areolar complex, previous surgery, anticipated radiotherapy and the condition of the patient’s tissues. Immediate implant reconstruction may not be the preferred approach for every patient, particularly where additional treatment could affect reconstruction outcomes. The decision to preserve nerves must also remain secondary to complete and appropriate cancer removal.
MedStar Georgetown reported that it is among approximately ten United States hospitals performing nipple-sparing mastectomy using the da Vinci SP system and the only institution in the Washington, D.C., region offering the procedure. That reported availability highlights the specialised nature of the approach, but it does not establish national procedural volumes or how quickly other hospitals are adopting the technique.
What are the potential hospital costs and adoption barriers for robotic breast reconstruction?
Expanding single-port robotic breast surgery requires more than purchasing an appropriate surgical platform. Hospitals must invest in surgeon training, multidisciplinary coordination, equipment maintenance and operating-room workflows suited to the procedure. Breast surgeons, reconstructive surgeons, anaesthesia teams and specialised nursing staff must work together to ensure that cancer treatment and reconstruction can be completed efficiently.
The longer operative times observed in some comparative studies are commercially relevant because operating-room capacity is a major hospital resource. Even if a procedure reduces incision size or improves certain patient-reported outcomes, additional surgical time can increase staffing and facility costs. Those expenses must be assessed against possible benefits involving recovery, hospital stay, complications and subsequent procedures.
Combining mastectomy with immediate reconstruction is already possible using conventional surgical methods. Consequently, the commercial value of robotic assistance must be evaluated against existing workflows rather than assuming that all four components become possible only through robotics. The differentiating features of the MedStar Georgetown approach are its concealed access site and the integration of multiple surgical objectives through that opening.
Reimbursement introduces further uncertainty. Existing payment arrangements for mastectomy and breast reconstruction do not necessarily provide additional compensation for robotic instrumentation or higher equipment costs. Hospitals considering broader deployment would need to determine whether potential improvements in patient experience and clinical outcomes justify the additional operating expenditure.
Intuitive Surgical, Inc. (NASDAQ: ISRG), the publicly traded manufacturer of the da Vinci SP system, could benefit from broader adoption of single-port surgery across appropriately supported specialties. However, the MedStar Georgetown announcement does not disclose a new equipment purchase, additional system installation or financial contribution to Intuitive Surgical. This individual case should therefore be viewed as an example of platform utilisation rather than a measurable revenue catalyst.
What evidence is needed before one-incision robotic mastectomy becomes a wider treatment option?
The most immediate need is systematic reporting of procedural and postoperative outcomes. Relevant measures include operating time, blood loss, surgical margin status, complications, implant outcomes, hospital stay and unplanned readmissions. These findings would help establish whether the combined surgical approach can be performed consistently beyond an individual patient case.
Sensory preservation deserves dedicated follow-up because it is a defining objective of the technique. Standardised assessments of nipple and breast sensation before surgery and at several postoperative intervals could help distinguish genuine preservation from temporary or partial recovery. Patient-reported measures involving pain, satisfaction and everyday functioning would provide additional information about whether the procedure delivers benefits meaningful to patients.
Longer-term oncological monitoring will also be necessary. Rates of local recurrence, disease-free survival and subsequent treatment requirements are essential when evaluating any change to established breast cancer surgery techniques. Appropriately designed prospective comparative studies would provide stronger evidence than individual case reports or institutional experience alone.
The June 25 operation demonstrates the technical feasibility of performing several important breast surgical components through a concealed 4-centimeter incision. It also illustrates the growing emphasis on preserving appearance and potentially sensation alongside conventional oncological objectives. However, MedStar Georgetown’s October announcement does not establish that this approach produces superior cancer control, reliably preserves breast sensation or reduces recovery time across a broader patient population.
For MedStar Georgetown University Hospital and the wider robotic surgery sector, the next meaningful development will be evidence that the procedure can be reproduced safely, with measurable patient benefits and acceptable resource requirements. The most important question is not simply whether surgeons can accomplish four objectives through one incision, but whether doing so provides outcomes that justify broader use alongside established breast cancer surgery techniques.
